

Korean firm Seegene expands influence in Italy's PCR diagnostic industry

16 April 2021 | News

Seegene's Italy subsidiary secures public procurement for 7.15 million COVID-19 diagnostic tests, the largest tender in history

South Korea based Seegene Inc. has said that its Italian subsidiary, the Arrow Diagnostics Srl, has secured the public procurement worth over EUR 89.3 million, the largest volume of tender in the history of its Italian branch since 2014.

Under the tender agreement, the Arrow Diagnostics will supply some 7.15 million COVID-19 diagnostic tests along with extraction reagents to the Extraordinary Commissioner for COVID-19 Emergency, or 'il commissario straordinario per l'emergenza COVID-19,' under the Italian Ministry of Defense. The COVID-19 diagnostic tests will be distributed to 17 regions including Lombardy, Tuscany, Veneto and Liguria.

Seegene's COVID-19 diagnostic test, the AllplexTM SARS-CoV-2 Assay is a unique multiplex real-time PCR assay capable of detecting a total of five target genes including four coronavirus genes (E gene, RdRP gene, N gene and S gene) and an exogenous control (entire whole process control) in a single reaction, allowing highly accurate results and maximize throughput for high volume testing. The diagnostic test has acquired CE-IVD mark in June of 2020.

The COVID-19 diagnostic tests as well as its extraction reagents have already been supplied to Europe's third largest economy—and is in the process of being allocated to regions nationwide since the start of April.